CAD 1.05
(-13.93%)
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2023 | - CAD | 0.0% |
2022 | - CAD | 0.0% |
2021 | - CAD | 0.0% |
2020 | - CAD | -100.0% |
2019 | 31.96 Thousand CAD | 0.0% |
2018 | - CAD | 0.0% |
2017 | - CAD | 0.0% |
2016 | - CAD | 0.0% |
2015 | - CAD | 0.0% |
2014 | - CAD | 0.0% |
2013 | - CAD | 0.0% |
Year | Long Term Debt | Long Term Debt Growth |
---|---|---|
2024 Q1 | - CAD | 0.0% |
2023 FY | - CAD | 0.0% |
2023 Q4 | - CAD | 0.0% |
2023 Q3 | - CAD | 0.0% |
2023 Q2 | - CAD | 0.0% |
2023 Q1 | - CAD | 0.0% |
2022 Q3 | - CAD | 0.0% |
2022 FY | - CAD | 0.0% |
2022 Q1 | - CAD | 0.0% |
2022 Q2 | - CAD | 0.0% |
2022 Q4 | - CAD | 0.0% |
2021 Q2 | - CAD | 0.0% |
2021 Q1 | - CAD | 0.0% |
2021 Q4 | - CAD | 0.0% |
2021 Q3 | - CAD | 0.0% |
2021 FY | - CAD | 0.0% |
2020 FY | - CAD | -100.0% |
2020 Q4 | - CAD | -100.0% |
2020 Q3 | 3000.00 CAD | -76.92% |
2020 Q2 | 13 Thousand CAD | -42.57% |
2020 Q1 | 22.63 Thousand CAD | -29.19% |
2019 FY | 31.96 Thousand CAD | 0.0% |
2019 Q3 | - CAD | 0.0% |
2019 Q4 | 31.96 Thousand CAD | 0.0% |
2019 Q1 | - CAD | 0.0% |
2019 Q2 | - CAD | 0.0% |
2018 Q3 | - CAD | 0.0% |
2018 Q4 | - CAD | 0.0% |
2018 FY | - CAD | 0.0% |
2018 Q1 | - CAD | 0.0% |
2018 Q2 | - CAD | 0.0% |
2017 Q2 | - CAD | 0.0% |
2017 Q1 | - CAD | 0.0% |
2017 Q3 | - CAD | 0.0% |
2017 FY | - CAD | 0.0% |
2017 Q4 | - CAD | 0.0% |
2016 Q2 | - CAD | 0.0% |
2016 Q1 | - CAD | 0.0% |
2016 FY | - CAD | 0.0% |
2016 Q4 | - CAD | 0.0% |
2016 Q3 | - CAD | 0.0% |
2015 Q2 | - CAD | 0.0% |
2015 Q4 | - CAD | 0.0% |
2015 Q1 | - CAD | 0.0% |
2015 FY | - CAD | 0.0% |
2014 FY | - CAD | 0.0% |
2013 FY | - CAD | 0.0% |
Name | Long Term Debt | Long Term Debt Difference |
---|---|---|
Appili Therapeutics Inc. | 875.2 Thousand CAD | 100.0% |
Eupraxia Pharmaceuticals Inc. | - CAD | NaN% |
Helix BioPharma Corp. | - CAD | NaN% |
Microbix Biosystems Inc. | 6.37 Million CAD | 100.0% |
Satellos Bioscience Inc. | - CAD | NaN% |
Oncolytics Biotech Inc. | 290 Thousand CAD | 100.0% |
Sernova Corp. | - CAD | NaN% |